Rituximab/bendamustine/cytarabine for transplant‐eligible patients with mantle cell lymphoma: A retrospective study

Rituximab/bendamustine/cytarabine for transplant‐eligible patients with mantle cell lymphoma: A retrospective study

Abstract Background Mantle cell lymphoma is considered an aggressive B‐cell lymphoma. The optimal induction regimen remains controversial as no randomized controlled trial has compared the efficacy of different induction therapies. Method Herein, we performed a retrospective analysis of the clinical...

Full description

Bibliographic Details
Main Authors: Yuki Shimizu, Daisuke Kaji, Otoya Watanabe, Kyosuke Yamaguchi, Kosei Kageyama, Yuki Taya, Aya Nishida, Kazuya Ishiwata, Shinsuke Takagi, Hisashi Yamamoto, Yuki‐Asano Mori, Atsushi Wake, Naoyuki Uchida, Shuichi Taniguchi, Go Yamamoto
Format: Article
Language:English
Published: Wiley 2023-06-01
Series:Cancer Medicine
Subjects:
effective and safe
induction therapy
mantle cell lymphoma
rituximab/bendamustine/cytarabine
transplant eligibility
Online Access:https://doi.org/10.1002/cam4.6114

Internet

https://doi.org/10.1002/cam4.6114

Similar Items